Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GALT
GALT logo

GALT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Galectin Therapeutics Inc (GALT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.210
1 Day change
5.24%
52 Week Range
7.130
Analysis Updated At
2026/05/01
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

GALT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The setup is mixed to weak: there is no AI Stock Picker or SwingMax buy signal today, the trend is still bearish on moving averages, fundamentals remain poor with negative earnings, and there has been no recent news or insider/congress buying to create a strong catalyst. The options market shows speculative activity, but it is not enough to override the weak technical and financial picture. Best action: hold and wait for a clearer trend reversal or a catalyst-driven setup.

Technical Analysis

Current pre-market price is 2.27, sitting just above S1 at 2.249 and below the pivot at 2.354, which suggests the stock is still trading in a weak zone. MACD histogram is slightly positive at 0.0111 but contracting, so momentum is not improving strongly. RSI_6 at 40.836 is neutral-to-weak, not signaling an oversold rebound. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which confirms the broader trend remains down. Near-term support is 2.249 and then 2.184, while resistance is 2.354 and 2.459. Overall technical trend: weak bearish with only a minor short-term stabilization.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is mixed. The open interest put-call ratio of 0.1 suggests call-heavy positioning in open interest, which is usually bullish on paper. However, the option volume put-call ratio of 2.19 shows more puts traded today than calls, indicating short-term bearish or hedging activity. Total option volume is also elevated versus the 30-day average, implying increased attention, but not a clean bullish signal. With no AI Stock Picker or SwingMax buy signal, options activity alone does not support an immediate buy.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
2

Positive Catalysts

  • ["No major news in the recent week, so there is no negative event pressure and no fresh headline risk.", "Pre-market price holding near support may suggest some short-term stabilization.", "Option open interest remains call-heavy overall, which can reflect longer-dated speculative optimism."]

Neutral/Negative Catalysts

  • ["No recent news catalyst to drive a re-rating.", "No AI Stock Picker signal today.", "No recent SwingMax signal.", "Bearish moving average alignment signals the trend is still down.", "Quarterly financials remain weak with negative net income and negative EPS.", "No recent insider buying, hedge fund accumulation, or congress trading support.", "Short-term option flow is put-heavy, suggesting bearish or defensive positioning."]

Financial Performance

Latest reported quarter: 2025/Q4. Revenue was 0, flat year over year, so there is no operating growth to support the stock. Net income was -5.562 million, down 53.77% YoY, and EPS was -0.09, down 52.63% YoY. Gross margin was 0. The latest quarter shows deterioration in profitability and no revenue traction, which is a weak fundamental profile for a long-term beginner investor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible trend in Wall Street estimates to support a buy case. Based on the available information, the Wall Street pros view would be cautious to negative: weak fundamentals, bearish technicals, and no catalyst. The pros for the stock are limited to speculative upside from option interest and potential rebound from oversold levels, while the cons are much stronger: no revenue growth, losses widening, no fresh news, and no bullish trading signals.

Wall Street analysts forecast GALT stock price to rise
1 Analyst Rating
Wall Street analysts forecast GALT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.210
sliders
Low
11
Averages
11
High
11
Current: 2.210
sliders
Low
11
Averages
11
High
11
H.C. Wainwright
Matthew Keller
Buy
maintain
$6 -> $11
AI Analysis
2025-12-17
Reason
H.C. Wainwright
Matthew Keller
Price Target
$6 -> $11
AI Analysis
2025-12-17
maintain
Buy
Reason
H.C. Wainwright analyst Matthew Keller raised the firm's price target on Galectin Therapeutics to $11 from $6 and keeps a Buy rating on the shares. The firm says recent biomarker data continue to strengthen confidence in Galectin's metabolic dysfunction-associated steatohepatitis program.
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$6
2025-06-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$6
2025-06-18
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Galectin Therapeutics with a Buy rating and $6 price target. Galectin's lead asset is belapectin, an intravenously administered galectin-3 inhibitor. Galectin-3 is a protein that plays a key role in cell signaling, differentiation, apoptosis, and inflammation, the analyst tells investors in a research note. The firm says that despite the company's setbacks, it believes "the stock can get back on track." It says belapectin is a "unique therapy targeting a clinically relevant molecule."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GALT
Unlock Now

People Also Watch